mHealth ALIBIRD: A Digital Health Care Model

Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares

Status: Completed

Conditions: Thoracic Neoplasms

Treatments: Device: ALIBIRD mHealth platform

Study type: Interventional

Funder types: Other

Identifiers

NCT05770869

mHA

Details and patient eligibility

About

The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.

Full description

The investigators have developed an innovative mHealth platform that provides personalized recommendations based on Patient Reported Outcomes (PROs) records and the study of patient´s nutrigenomics and gut microbiome. The usability of the ALIBIRD mHealth platform prototype is being tested in a 28-week pilot study carried out at Infanta Sofía Hospital. A small group of stage IV thoracic neoplasms patients (n=20) were asked to participate. All the participants gave informed consent.

Enrollment: 20 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with thoracic neoplasms, histologically or cytologically confirmed.
• < 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Patients receiving cancer treatment: chemotherapy, chemotherapy-immunotherapy, immunotherapy or biological therapy.
• Patients with internet access and intermediate level in the use of technology (Smartphone, mobile applications, wearable)
• Signed informed consent.

Exclusion criteria

• Patients with symptomatic brain metastases.
• Patients with neurological impairment, dementia or psychiatric disorders.
• Patients unable to follow the protocol due to psychological, social or geographic reasons.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

ALIBIRD mHealth platform

Experimental group

Description:

Participants are followed-up using the ALIBIRD mHealth platform. The ALIBIRD platform is made up of a mobile application for patients and a web application for the healthcare team. Through the ALIBIRD mobile application, patients regularly register Patients Reported Outcomes (PROs) and Patients Reported Outcome Measures (PROMs) regarding lifestyle (diet, physical activity, sleep, mood), and get access to individualized recommendations in order to assume more responsibility for achieving the best outcomes from their care. Moreover, the patient application includes features for tracking the appearance of symptoms, with alerts sent to the healthcare team in response to these parameters. In addition, the application contains articles and educational information.

Treatment:

Device: ALIBIRD mHealth platform